Asset Details
Do you wish to reserve the book?
Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review
Do you wish to request the book?
Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review
2020
Overview
Chronic kidney disease (CKD) is associated with the development of mineral bone disorder (MBD), osteoporosis, and fragility fractures. Among CKD patients, adynamic bone disease or low bone turnover is the most common type of renal osteodystrophy. The consequences of CKD-MBD include increased fracture risk, greater morbidity, and mortality. Thus, the goal is to prevent the occurrences of fractures by means of alleviating CKD-induced MBD and treating subsequent osteoporosis. Changes in mineral and humoral metabolism as well as bone structure develop early in the course of CKD. CKD-MBD includes abnormalities of calcium, phosphorus, PTH, and/or vitamin D; abnormalities in bone turnover, mineralization, volume, linear growth, or strength; and/or vascular or other soft tissue calcification. In patients with CKD-MBD, using either DXA or FRAX to screen fracture risk should be considered. Biomarkers such as bALP and iPTH may assist to assess bone turnover. Before initiating an antiresorptive or anabolic agent to treat osteoporosis in CKD patients, lifestyle modifications, such as exercise, calcium, and vitamin D supplementation, smoking cessation, and avoidance of excessive alcohol intake are important. Managing hyperphosphatemia and SHPT are also crucial. Understanding the complex pathogenesis of CKD-MBD is crucial in improving one’s short- and long-term outcomes. Treatment strategies for CKD-associated osteoporosis should be patient-centered to determine the type of renal osteodystrophy. This review focuses on the mechanism, evaluation and management of patients with CKD-MBD. However, further studies are needed to explore more details regarding the underlying pathophysiology and to assess the safety and efficacy of agents for treating CKD-MBD.
Publisher
MDPI
Subject
/ Chronic Kidney Disease-Mineral and Bone Disorder - complications
/ Chronic Kidney Disease-Mineral and Bone Disorder - etiology
/ Chronic Kidney Disease-Mineral and Bone Disorder - metabolism
/ Chronic Kidney Disease-Mineral and Bone Disorder - physiopathology
/ Fractures, Bone - complications
/ Humans
/ Kidney Diseases - complications
/ Osteoporosis - physiopathology
/ Renal Dialysis - adverse effects
/ Renal Insufficiency, Chronic - complications
/ Renal Insufficiency, Chronic - diagnostic imaging
/ Renal Insufficiency, Chronic - physiopathology
/ Renal Insufficiency, Chronic - therapy
/ Review
